Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

KEEN to lose weight in 2025? So are almost half of our readers. While weight-loss jabs, similar to Ozempic, boomed in ...

As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk. Reuters Eli Lilly said Wednesday that its obesity drug Zepbound ...

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Indiana’s Medicaid program estimates the Biden administration’s proposal to expand coverage of weight-loss treatment for ...

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for monthly dosing and no titration requirement.

CHICAGO As 2025 begins and millions of Americans start working to keep their New Year’s resolutions, Attorney General Kwame ...